Payment overview · 2025
General Payments
$353.54
14 reported records · 9 companies
Healthcare provider profile · identity verified
Steven E Catlett, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · COACHELLA, CA · NPI 1629038047
Verified facts
What the public records show
CMS Open Payments records show Steven E Catlett, M.D. received $353.54 in general payments during 2025 across 14 reported records.
Novo Nordisk Inc accounted for 55.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Xifaxan.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $194.41 | 55.0% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.47 | 12.0% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $20.23 | 5.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.44 | 5.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.16 | 5.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.71 | 5.0% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $14.61 | 4.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.01 | 4.0% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $12.50 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $353.54 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $169.53 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $58.40 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $42.47 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $12.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 50 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | 14 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 780 | 277 |
| Metformin Hcl | Metformin Hcl | 487 | 171 |
| Omeprazole | Omeprazole | 343 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 326 | 121 |
| Lisinopril | Lisinopril | 307 | 114 |
| Gabapentin | Gabapentin | 304 | 100 |
| Losartan Potassium | Losartan Potassium | 246 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 239 | 76 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 204 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 188 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 167 | 56 |
| Simvastatin | Simvastatin | 161 | 52 |
| Alendronate Sodium | Alendronate Sodium | 147 | 51 |
| Pioglitazone Hcl | Pioglitazone Hcl | 143 | 52 |
| Baclofen | Baclofen | 140 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 45 |
| Meclizine Hcl | Meclizine Hcl | 132 | 48 |
| Meloxicam | Meloxicam | 131 | 38 |
| Benazepril Hcl | Benazepril Hcl | 122 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 106 | 36 |
| Ibuprofen | Ibuprofen | 105 | 51 |
| Furosemide | Furosemide | 102 | 30 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 101 | 30 |
| Fenofibrate | Fenofibrate,micronized | 101 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 101 | 33 |
| Mirtazapine | Mirtazapine | 95 | 34 |
| Carvedilol | Carvedilol | 93 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 92 | 43 |
| Allopurinol | Allopurinol | 90 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 84 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 30 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 81 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 79 | 30 |
| Donepezil Hcl | Donepezil Hcl | 78 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 24 |
| Montelukast Sodium | Montelukast Sodium | 65 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 23 |
| Glimepiride | Glimepiride | 61 | 21 |
| Famotidine | Famotidine | 59 | 21 |
| Sertraline Hcl | Sertraline Hcl | 59 | 19 |
| Jardiance | Empagliflozin | 58 | 17 |
| Januvia | Sitagliptin Phosphate | 55 | 17 |
| Atenolol | Atenolol | 52 | 18 |
| Nitroglycerin | Nitroglycerin | 52 | 17 |
| Ozempic | Semaglutide | 50 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 17 |
| Metformin Hcl Er | Metformin Hcl | 46 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 41 |
| Fenofibrate | Fenofibrate | 43 | 12 |
| Naproxen | Naproxen | 43 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 42 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 12 |
| Clonidine Hcl | Clonidine Hcl | 38 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 18 |
| Nifedipine Er | Nifedipine | 36 | 11 |
| Trazodone Hcl | Trazodone Hcl | 36 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 25 |
| Linzess | Linaclotide | 33 | 12 |
| Finasteride | Finasteride | 32 | 13 |
| Eliquis | Apixaban | 31 | 15 |
| Glipizide | Glipizide | 31 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | 11 |
| Droplet Pen Needle | Pen Needle, Diabetic | 23 | 13 |
| Pregabalin | Pregabalin | 23 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | 13 |
| Phenobarbital | Phenobarbital | 21 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Potassium Chloride | Potassium Chloride | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Procto-Med Hc | Hydrocortisone | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $353.54 · 14 records | Novo Nordisk Inc | ARISTADA, CeQur Simplicity, Kerendia, LYBALVI, MOUNJARO, Omnipod, Ozempic, Rybelsus, TRELEGY ELLIPTA, WAINUA, Wegovy, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error